WORLDCOIN-FOUNDATION
15.5.2024 15:03:34 CEST | Business Wire | Press release
The Worldcoin Foundation today announced it launched and is open sourcing a novel secure multi-party computation (SMPC) system. The system, available now in a GitHub repository for any organization to use, aims to set a new standard for data protection, including the protection of biometric data. The Worldcoin Foundation also announced that, after the migration of iris codes to the new SMPC system, the previous uniqueness-checking system, including iris codes, was securely deleted.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240515285506/en/
Worldcoin Foundation Launches, Open Sources "Perfect Secrecy" SMPC System to Help Organizations Strengthen Biometric Data Security Protections (Graphic: Business Wire)
Biometric authentication use increases as data breach frequency and impact rise
Organizations in the private and public sector increasingly require and use consumers’ biometric data for everyday services and activities, from building access and airport security to logging into healthcare and financial services apps. Underscoring the increase, a Fortune Business Insights report projected the global biometric system market size to reach $76.70 billion USD in 2029, 2.5x its total of $30.77 billion in 2022.
Meanwhile, research from MIT Professor Stuart Madnick indicates a 20% increase in data breaches from 2022 to 2023 while globally the number of victims of such breaches doubled over the same time period.
The convergence of these trends suggests a need to further advance data protection technologies. While Worldcoin is neither an authentication nor an identification use case for biometrics (the Worldcoin Foundation does not know the identity of their users), the Foundation’s new open source SMPC system can serve as a building block to set a new standard in biometric data security.
Worldcoin Foundation’s SMPC system
SMPC has been lauded by privacy and security experts alike. It can be thought of as taking one secret and sharing it in multiple parts across different parties for increased protection. Importantly, none of the individual parts alone say anything about the original secret, thus making it impossible for any individual party to decrypt the secret.
This SMPC approach demonstrates perfect information-theoretic security, meaning it is effective even against quantum-computing. SMPC systems have generally been too resource-intensive to be effectively used for large complex computations. This is why, despite their impressive privacy protective qualities, they have not yet seen extensive use in biometric template protection.
The Worldcoin Foundation, along with contributor-technologists from TACEO and Tools for Humanity, have successfully architected a new implementation of SMPC to address the scale and cost constraints that have previously hindered others. The new SMPC system, which encrypts iris codes into secret shares held by multiple parties, enabled the Worldcoin Foundation to permanently delete iris codes generated through its previous uniqueness-checking system.
“The community supporting Worldcoin will never stop developing, testing and deploying the most advanced technologies focusing on security, privacy and data protection as it works to improve trust online and increase access to the global economy,” said Jannick Preiwisch, Data Protection Officer of the Worldcoin Foundation. “Implementation of the new SMPC system enabled the Worldcoin Foundation to delete old iris codes by permanently encrypting them to SMPC shares that by themselves cannot be related to an identified person. The development of this new system demonstrates an unparalleled commitment to further compliance with the EU General Data Protection Regulation and other data protection regimes across the world. It also complements advancements aimed at providing consumers increased choice and control over their data including personal custody and the ability to unverify their World IDs.”
About the Worldcoin Foundation
The Worldcoin Foundation, a steward of the Worldcoin protocol, aims to realize more inclusive, fair and just institutions of governance and of the global digital economy.
About the Worldcoin Protocol
The Worldcoin protocol is intended to be the world’s largest, most inclusive identity and financial public utility and to be accessible by everyone. Worldcoin was originally conceived by Sam Altman, Alex Blania and Max Novendstern. The Worldcoin protocol is designed to empower individuals and organizations around the world with the tools they need to participate in the digital economy and advance humanity's progress. Find out more about Worldcoin at www.worldcoin.org, on Twitter/X, Discord, YouTube and Telegram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515285506/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom